ACAlexandra Cousido-Siah

Alexandra Cousido-Siah

*This is an algorithmically generated author record based on publicly available information.

Alexandra Cousido-Siah has a total of 65 co-authors. Here are the top co-authors by number of shared publications:

  • Alberto Podjarny

    Department of Integrative Biology, IGBMC, CNRS, INSERM, Université de Strasbourg, Illkirch, France

    5 shared publications
  • Gilles Trave

    Équipe Labellisée Ligue 2015, Département de Biologie Structurale Intégrative, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM U1258/CNRS UMR 7104/Université de Strasbourg, Illkirch, France

    4 shared publications
  • André Mitschler

    Department of Integrated Structural Biology, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM (U1258), University of Strasbourg, CNRS, UMR 7104, Illkirch, France

    3 shared publications
  • Eduardo I. Howard

    Instituto de Fisica de Liquidos y Sistemas Biologicos (UNLP‐CONICET) Buenos Aires Argentina

    3 shared publications
  • Gergo Gogl

    Équipe Labellisée Ligue 2015, Département de Biologie Structurale Intégrative, Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), INSERM U1258/CNRS UMR 7104/Université de Strasbourg, Illkirch, France

    3 shared publications
  • Angel Rodriguez de Lera

    CINBIO, Departamento de Química Orgánica, Universidade de Vigo, IBIV, As Lagoas-Marcosende, 36310 Vigo, Spain

    2 shared publications

Latest Publications

  • Open Access

    Structural analysis of HERC2/UBE3A and HERC2/DOCK10 complexes provides new insights into the molecular basis of Angelman, Angelman-like and Dup15q Syndromes

    by Auguste Demenge, JiaWen Lim, Arpoudamarie Roc, Boglarka Zambo, Gergo Gogl, Alexandra Cousido-Siah, Alastair Mc Ewen, Anna Bonhoure, Camille Kostmann, Christine Fagotto-Kaufmann, et al.

    UBE3A and HERC2 are two mutually interacting HECT E3 Ubiquitin ligases whose genes are altered in 15q11.2-13.1 Duplication (Dup15q) Syndrome, Angelman Syndrome (AS) and other phenotypically-related mental retardation syndromes. Using quantitative binding assays, X-ray crystallography and sequence conservation analysis, we show that the HERC2/UBE3A complex occurs in probably most animals with a central nervous system, via a conserved interface involving the RLD2 domain of HERC2 and a “DxDKDxD” motif of UBE3A. We found that HERC2 also recognizes and binds to similar DxDKDxD motifs within a handful of other proteins relevant to brain development (DOCK10, PCM1, USP35, BAZ2B, ARID4A, ARIP4, RERE and MYT1). We further investigated the interaction of HERC2 with DOCK10, a RAC1- and CDC42-GEF protein that regulates dendritic spine morphogenesis in hippocampal neurons. Both disruption of the HERC2-binding motif in DOCK10 and knockdown of HERC2 affected the GEF activity of DOCK10. We also show that the DOCK10-induced dendritic spine formation is dependent on its ability to bind HERC2. Structural modeling of full-length DOCK10, free or bound to either RLD2, CDC42 or RAC1 indicates that the GEF activation of full-length DOCK10 requires a conformational change that is stimulated by binding to HERC2. Based on our data, we propose that under pathological conditions, in developing brains with an abnormal dosage of either HERC2 or its dominant partner UBE3A, increased or decreased amounts of HERC2/DOCK10 complexes could lead to altered GTPase activation. This in turn could affect dendritic spine formation and neurodevelopment.

  • Lipid exchange in crystal‐confined fatty acid binding proteins: X‐ray evidence and molecular dynamics explanation

    by H. Ariel Alvarez, Alexandra Cousido‐Siah, Yanis R. Espinosa, Alberto Podjarny, C. Manuel Carlevaro, Eduardo Howard

    Fatty acid binding proteins (FABPs) are responsible for the long-chain fatty acids (FAs) transport inside the cell. However, despite the years, since their structure is known and the many studies published, there is no definitive answer about the stages of the lipid entry-exit mechanism. Their structure forms a & beta;$$ \beta $$-barrel of 10 anti-parallel strands with a cap in a helix-turn-helix motif, and there is some consensus on the role of the so-called portal region, involving the second & alpha;$$ \alpha $$-helix from the cap (& alpha;$$ \alpha $$2), & beta;$$ \beta $$C-& beta;$$ \beta $$D, and & beta;$$ \beta $$E-& beta;$$ \beta $$F turns in FAs exchange. To test the idea of a lid that opens, we performed a soaking experiment on an h-FABP crystal in which the cap is part of the packing contacts, and its movement is strongly restricted. Even in these conditions, we observed the replacement of palmitic acid by 2-Bromohexadecanoic acid (Br-palmitic acid). Our MD simulations reveal a two-step lipid entry process: (i) The travel of the lipid head through the cavity in the order of tens of nanoseconds, and (ii) The accommodation of its hydrophobic tail in hundreds to thousands of nanoseconds. We observed this even in the cases in which the FAs enter the cavity by their tail. During this process, the FAs do not follow a single trajectory, but multiple ones through which they get into the protein cavity. Thanks to the complementary views between experiment and simulation, we can give an approach to a mechanistic view of the exchange process.


  • Open Access

    Evidence for direct interaction between the oncogenic proteins E6 and E7 of high-risk human papillomavirus (HPV)

    by JiaWen Lim, Hauke Lilie, Hubert Kalbacher, Nora Roos, Desiree Isabella Frecot, Maximilian Feige, Marcel Conrady, Tobias Votteler, Alexandra Cousido-Siah, Giada Corradini Bartoli, et al.


  • A scalable strategy to solve structures of PDZ domains and their complexes

    by Alexandra Cousido-Siah, Laura Carneiro, Camille Kostmann, Peter Ecsedi, Laszlo Nyitray, Gilles Trave, Gergo Gogl

    The human PDZome represents one of the largest globular domain families in the human proteome, with 266 instances. These globular domains typically interact with C-terminal peptide motifs found in thousands of human proteins. Despite previous efforts, not all PDZ domains have experimentally solved structures and most of their complexes remain to be solved. Here, a simple and cost-effective strategy is proposed for the crystallization of PDZ domains and their complexes. A human annexin A2 fusion tag was used as a crystallization chaperone and the structures of nine PDZ domains were solved, including five domains that had not yet been solved. Finally, these novel experimental structures were compared with AlphaFold predictions and it is speculated how predictions and experimental methods could cooperate in order to investigate the structural landscapes of entire domain families and interactomes.


  • Open Access

    Conformational editing of intrinsically disordered protein by α-methylation

    by Valentin Bauer, Boris Schmidtgall, Gergő Gógl, Jozica Dolenc, Judit Osz, Yves Nominé, Camille Kostmann, Alexandra Cousido-Siah, André Mitschler, Natacha Rochel, et al.

    Control of protein conformation was achieved for intrinsically disordered protein by incorporation of α-methylated amino acids.


  • Structural Basis of Outstanding Multivalent Effects in Jack Bean α‐Mannosidase Inhibition

    by Eduardo Howard, Alexandra Cousido‐Siah, Mathieu L. Lepage, Jérémy P. Schneider, Anne Bodlenner, André Mitschler, Alessandra Meli, Irene Izzo, H. Ariel Alvarez, Alberto Podjarny, et al.

    Multivalent design of glycosidase inhibitors is a promising strategy for the treatment of diseases involving enzymatic hydrolysis of glycosidic bonds in carbohydrates. An essential prerequisite for successful applications is the atomic‐level understanding of how outstanding binding enhancement occurs with multivalent inhibitors. Herein we report the first high‐resolution crystal structures of the Jack bean α‐mannosidase (JBα‐man) in apo and inhibited states. The three‐dimensional structure of JBα‐man in complex with the multimeric cyclopeptoid‐based inhibitor displaying the largest binding enhancements reported so far provides decisive insight into the molecular mechanisms underlying multivalent effects in glycosidase inhibition.


  • Structural basis for the inhibition of AKR1B10 by the C3 brominated TTNPB derivative UVI2008

    by Francesc X. Ruiz, Isidro Crespo, Susana Álvarez, Sergio Porté, Joan Giménez-Dejoz, Alexandra Cousido-Siah, André Mitschler, Ángel R. de Lera, Xavier Parés, Alberto Podjarny, et al.


  • Open Access

    Identification of a novel polyfluorinated compound as a lead to inhibit the human enzymes aldose reductase and AKR1B10: structure determination of both ternary complexes and implications for drug design

    by Alexandra Cousido-Siah, Francesc X. Ruiz, André Mitschler, Sergio Porté, Ángel R. de Lera, María J. Martín, Sonia Manzanaro, Jesús A. de la Fuente, Felix Terwesten, Michael Betz, et al.

    Aldo-keto reductases (AKRs) are mostly monomeric enzymes which fold into a highly conserved (α/β)8 barrel, while their substrate specificity and inhibitor selectivity are determined by interaction with residues located in three highly variable external loops. The closely related human enzymes aldose reductase (AR or AKR1B1) and AKR1B10 are of biomedical interest because of their involvement in secondary diabetic complications (AR) and in cancer, e.g. hepatocellular carcinoma and smoking-related lung cancer (AKR1B10). After characterization of the IC50 values of both AKRs with a series of polyhalogenated compounds, 2,2′,3,3′,5,5′,6,6′-octafluoro-4,4′-biphenyldiol (JF0064) was identified as a lead inhibitor of both enzymes with a new scaffold (a 1,1′-biphenyl-4,4′-diol). An ultrahigh-resolution X-ray structure of the AR–NADP+–JF0064 complex has been determined at 0.85 Å resolution, allowing it to be observed that JF0064 interacts with the catalytic residue Tyr48 through a negatively charged hydroxyl group (i.e. the acidic phenol). The non-competitive inhibition pattern observed for JF0064 with both enzymes suggests that this acidic hydroxyl group is also present in the case of AKR1B10. Moreover, the combination of surface lysine methylation and the introduction of K125R and V301L mutations enabled the determination of the X-ray crystallographic structure of the corresponding AKR1B10–NADP+–JF0064 complex. Comparison of the two structures has unveiled some important hints for subsequent structure-based drug-design efforts.